Turning Point Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2013)
Status: Acquired by Bristol-Myers Squibb (2022)

Organization Overview

First Clinical Trial
2016
NCT03154619
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TR Therapeutics, Inc. | Turning Point | Turning Point Theraperutics | Turning Point Therapeutics | Turning Point Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Leg Ulcer (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Thyroid Neoplasms (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Venous Insufficiency (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 12